Moxalactam is not more active on extended spectrum&amp;nbsp;&lt;br /&gt;&lt;span style="text-align: justify"&gt;&amp;beta;&lt;/span&gt;-lactamase (ESBL) producing bacteria than on non-ESBL producers

Singh, Bhoj Raj

doi:10.2147/idr.s163186

Search citation statements

Order By: Relevance

Paper Sections

Select...

Introduction1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2018

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to its unique antimicrobial activity and novel structure among the synthetic antibiotics, the 1-oxacephem core structure as an important pharmaceutical scaffold has attracted immense interest from medicinal chemists [4][5][6]. A variety of synthetic compounds prepared from the 1-oxacephem intermediate, including prominent antibiotics such as Flomoxef, Moxalactam, and OCP-9-176 ( Figure 1), have a broad spectrum of activity against Gram-positive and Gram-negative aerobic and anaerobic bacteria [7][8][9].…”

Section: Introductionmentioning

confidence: 99%

(1R,5S)-6-(4-Methyl-2-oxo-2,5-dihydrofuran-3-yl)-3-phenyl-4-oxa-2,6-diazabicyclo[3.2.0]hept-2-en-7-one

Pham

Tippin

et al. 2018

Molbank

View full text Add to dashboard Cite

Efficient large-scale and feasible industrial synthesis of the 1-oxacephem core structure from 6-aminopenicillanic acid (6-APA) has been reported for several decades. Via the industrial synthesis route, a byproduct (compound 9) containing a butenolide unit was purified and characterized by NMR and HRMS in this work. It is worth noting that compound 9 is an entirely new compound. Additionally, a plausible mechanism and effects on the formation of 9 by different Lewis acids were proposed. The discovery of compound 9 could improve the purity of this feasible industrial synthesis and provide considerable cost savings.

show abstract